| Chemical Properties | Back Directory | [density ]
1.307±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C, sealed storage, away from moisture and light | [solubility ]
DMSO : 50 mg/mL (49.89 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.08±0.40(Predicted) | [color ]
Light yellow to green yellow |
| Hazard Information | Back Directory | [Uses]
XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK[1]. | [Biological Activity]
XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity[1].
XY028-133 (1 and 3 μM, 24 h) significantly decreases CDK4/6, Cyclin A, PLK1 and pRb protein levels in A375 cells[1]. | [IC 50]
CDK4; CDK6 | [storage]
Store at -20°C, sealed storage, away from moisture and light | [References]
[1]. JIN, Jian, et al. COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER. Patent. US2017/065027. |
|
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
|